- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04741971
Whether Probiotics Use in Neonate and Infant Improve Their Mother's Life Quality
February 4, 2021 updated by: Yu-Chao Hsiao, Buddhist Tzu Chi General Hospital
Postpartum depression and poor quality of life during postpartum were an vital issue in recent years.
Infant's health condition was thought to be a possible reasons related mother's postpartum quality of life, and functional gastrointestinal disorders such as infantile colic and regurgitation were common problem during infant period.
Previous study revealed that probiotics may improve the infant's discomfort caused by functional gastrointestinal disorders.
Thus, this study aimed to investigate whether probiotics use in neonate and infant improve their mother's life quality?
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
This is single blinded intervention study.
The investigators will invite mother to participate in the project after giving birth.
At week 0, mother who meet the eligibility criteria will be randomized in a single-blind study in a 1:1 ratio to probiotics with Vit.
D3 (five drops per day) or Vit.
D3 (placebo) (single drop per day) for 90 days.
The follow-up will be at the 1, 3 and 6 months all the subjects.
Study Type
Interventional
Enrollment (Anticipated)
220
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yu-Chao Hsiao
- Phone Number: 12777 886-3-8561825
- Email: u9602041@cmu.edu.tw
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 day to 50 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
<Participants of neonates>
Inclusion Criteria :
- Gestational age more than 37 to less than 41 weeks
- Age less than 1 week on entry into the study
- Birth weight adequate for gestational age
- Apgar score of more than 8 at 10 minutes
Exclusion Criteria:
- Congenital disorders and/or clinical or physical alterations at clinical examination
- Antibiotic or probiotic administration before inclusion
- Admission to ICU
<Participants of neonates' mother>
Inclusion Criteria:
- Aged between 20-50 and baby included in our study
Exclusion Criteria:
- Diagnosed as psychiatric disease during antepartum period or before pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Probiotics group
Will give Probiotics with Vit.D 3
|
Will give Probiotics with Vitamin D3 one drop per day for 90 days
|
Placebo Comparator: Non-probiotics group
Will give Vit. D3 as placebo
|
Will give Vitamin D3 five drops per day for 90 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maternal Sleep Quality
Time Frame: at their child birth
|
Maternal Sleep Quality assessed by the Pittsburgh Sleep Quality Index (PSQI): a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.
In scoring the PSQI, there are seven component scores with each scored 0 (no difficulty) to 3 (severe difficulty).
The component scores are summed to produce total score (range 0 to 21).
Higher scores indicate worse sleep quality.
|
at their child birth
|
Maternal Sleep Quality
Time Frame: at their child 1-month-old
|
Maternal Sleep Quality assessed by the Pittsburgh Sleep Quality Index (PSQI): a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.
In scoring the PSQI, there are seven component scores with each scored 0 (no difficulty) to 3 (severe difficulty).
The component scores are summed to produce total score (range 0 to 21).
Higher scores indicate worse sleep quality.
|
at their child 1-month-old
|
Maternal Sleep Quality
Time Frame: at their child 3-month-old
|
Maternal Sleep Quality assessed by the Pittsburgh Sleep Quality Index (PSQI): a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.
In scoring the PSQI, there are seven component scores with each scored 0 (no difficulty) to 3 (severe difficulty).
The component scores are summed to produce total score (range 0 to 21).
Higher scores indicate worse sleep quality.
|
at their child 3-month-old
|
Maternal Sleep Quality
Time Frame: at their child 6-month-old
|
Maternal Sleep Quality assessed by the Pittsburgh Sleep Quality Index (PSQI): a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.
In scoring the PSQI, there are seven component scores with each scored 0 (no difficulty) to 3 (severe difficulty).
The component scores are summed to produce total score (range 0 to 21).
Higher scores indicate worse sleep quality.
|
at their child 6-month-old
|
Maternal quality of life
Time Frame: at their child birth
|
Maternal quality of life assessed by World Health Organization Quality of Life (WHOQOL) questionnaire - Brief, Taiwan version: a questionnaire including 28 items with each score 0-4.
Higher score indicate better quality of life.
|
at their child birth
|
Maternal quality of life
Time Frame: at their child 1-month-old
|
Maternal quality of life assessed by World Health Organization Quality of Life (WHOQOL) questionnaire - Brief, Taiwan version: a questionnaire including 28 items with each score 0-4.
Higher score indicate better quality of life.
|
at their child 1-month-old
|
Maternal quality of life
Time Frame: at their child 3-month-old
|
Maternal quality of life assessed by World Health Organization Quality of Life (WHOQOL) questionnaire - Brief, Taiwan version: a questionnaire including 28 items with each score 0-4.
Higher score indicate better quality of life.
|
at their child 3-month-old
|
Maternal quality of life
Time Frame: at their child 6-month-old
|
Maternal quality of life assessed by World Health Organization Quality of Life (WHOQOL) questionnaire - Brief, Taiwan version: a questionnaire including 28 items with each score 0-4.
Higher score indicate better quality of life.
|
at their child 6-month-old
|
Maternal risk of postnatal depression
Time Frame: at their child birth
|
Maternal risk of postnatal depression assessed by Edinburgh Postnatal Depression Scale: a set of 10 screening questions with each score 0 to 3 that can indicate whether a parent has symptoms that are common in women with depression and anxiety during pregnancy and in the year following the birth of a child.
Higher score indicate higher risk of postnatal depression.
|
at their child birth
|
Maternal risk of postnatal depression
Time Frame: at their child birth 1-month-old
|
Maternal risk of postnatal depression assessed by Edinburgh Postnatal Depression Scale: a set of 10 screening questions with each score 0 to 3 that can indicate whether a parent has symptoms that are common in women with depression and anxiety during pregnancy and in the year following the birth of a child.
Higher score indicate higher risk of postnatal depression.
|
at their child birth 1-month-old
|
Maternal risk of postnatal depression
Time Frame: at their child birth 3-month-old
|
Maternal risk of postnatal depression assessed by Edinburgh Postnatal Depression Scale: a set of 10 screening questions with each score 0 to 3 that can indicate whether a parent has symptoms that are common in women with depression and anxiety during pregnancy and in the year following the birth of a child.
Higher score indicate higher risk of postnatal depression.
|
at their child birth 3-month-old
|
Maternal risk of postnatal depression
Time Frame: at their child birth 6-month-old
|
Maternal risk of postnatal depression assessed by Edinburgh Postnatal Depression Scale: a set of 10 screening questions with each score 0 to 3 that can indicate whether a parent has symptoms that are common in women with depression and anxiety during pregnancy and in the year following the birth of a child.
Higher score indicate higher risk of postnatal depression.
|
at their child birth 6-month-old
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neonate and infant' condition of functional gastrointestinal disorders
Time Frame: at baby's 1-month-old
|
Neonate and infant' condition of functional gastrointestinal disorders including infantile colic and regurgitation assessed by the questionnaires according to ROME-IV criteria, and higher score indicate worse condition of functional gastrointestinal disorders in infancy.
|
at baby's 1-month-old
|
Neonate and infant' condition of functional gastrointestinal disorders
Time Frame: at baby's 3-month-old
|
Neonate and infant' condition of functional gastrointestinal disorders including infantile colic and regurgitation assessed by the questionnaires according to ROME-IV criteria, and higher score indicate worse condition of functional gastrointestinal disorders in infancy.
|
at baby's 3-month-old
|
Neonate and infant' condition of functional gastrointestinal disorders
Time Frame: at baby's 6-month-old
|
Neonate and infant' condition of functional gastrointestinal disorders including infantile colic and regurgitation assessed by the questionnaires according to ROME-IV criteria, and higher score indicate worse condition of functional gastrointestinal disorders in infancy.
|
at baby's 6-month-old
|
Neonate and infant' diaper dermatitis
Time Frame: at baby's 1-month-old
|
Neonate and infant' diaper dermatitis assessed by the self-rated questionnaire to determine the condition of diaper dermatitis.
|
at baby's 1-month-old
|
Neonate and infant' diaper dermatitis
Time Frame: at baby's 3-month-old
|
Neonate and infant' diaper dermatitis assessed by the self-rated questionnaire to determine the condition of diaper dermatitis.
|
at baby's 3-month-old
|
Neonate and infant' diaper dermatitis
Time Frame: at baby's 6-month-old
|
Neonate and infant' diaper dermatitis assessed by the self-rated questionnaire to determine the condition of diaper dermatitis.
|
at baby's 6-month-old
|
Neonate and infant' atopic dermatitis
Time Frame: at baby's 1-month-old
|
Neonate and infant' atopic dermatitis assessed by the self-rated questionnaire to determine the condition of atopic dermatitis
|
at baby's 1-month-old
|
Neonate and infant' atopic dermatitis
Time Frame: at baby's 3-month-old
|
Neonate and infant' atopic dermatitis assessed by the self-rated questionnaire to determine the condition of atopic dermatitis
|
at baby's 3-month-old
|
Neonate and infant' atopic dermatitis
Time Frame: at baby's 6-month-old
|
Neonate and infant' atopic dermatitis assessed by the self-rated questionnaire to determine the condition of atopic dermatitis
|
at baby's 6-month-old
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Yu-Hsun Chang, Department of Pediatrics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation,Taiwan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 18, 2021
Primary Completion (Anticipated)
December 31, 2024
Study Completion (Anticipated)
December 31, 2024
Study Registration Dates
First Submitted
January 12, 2021
First Submitted That Met QC Criteria
February 4, 2021
First Posted (Actual)
February 5, 2021
Study Record Updates
Last Update Posted (Actual)
February 5, 2021
Last Update Submitted That Met QC Criteria
February 4, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P00001711
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Will share all IPD
IPD Sharing Time Frame
May be on December 2024
IPD Sharing Access Criteria
Will be published
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaRecruitingImprove Quality of LifeItaly
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Linkoeping UniversityRecruiting
-
South Valley UniversityActive, not recruitingDeterminants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRSHealth Related Quality of LifeEgypt
-
Region VästmanlandUnknownHealth Related Quality of Life
Clinical Trials on Probiotics group
-
Lingfen Xu, MDCompleted
-
GenMont Biotech IncorporationFu Jen Catholic University HospitalRecruitingNon-Alcoholic Fatty Liver DiseaseTaiwan
-
Universiti Sains MalaysiaMorinaga Milk Industry Co., LTDCompletedIrritable Bowel Syndrome | Abdominal Pain | Small Intestinal Bacterial Overgrowth
-
Glac Biotech Co., LtdCompletedMetabolic SyndromeTaiwan
-
TCI Co., Ltd.Recruiting
-
University of Milano BicoccaCompleted
-
GenMont Biotech IncorporationChia Nan University of Pharmacy and ScienceCompleted
-
Arkansas Children's Hospital Research InstituteCompleted
-
Chr HansenAarhus University HospitalCompletedInfant Development | Gut MicrobiomeDenmark
-
Zealand University HospitalHolbaek Sygehus; Chr Hansen; Dept. of Microbiology, Slagelse University Hospital... and other collaboratorsCompleted